Menlo Park rare lung condition startup lands big deal with Italian biopharma

A small Menlo Park startup focused on a drug-device to treat a condition that arises in some lung and stem cell transplant patients scored a potential half-billion-dollar buyout by an Italy-based drug company. Breath Therapeutics Inc., which also has offices and labs in Munich, Germany, will receive an initial $156 million — or 140 million euros — so Zambon S.p.A. can get control of an inhaled form of a common transplant rejection drug and the nebulizer that delivers it. The ultimate payout…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news